Netramark signs NetraAI contract with biopharm firm

Executive Summary

• Netramark Holdings Inc. has signed a contract with a leading global biopharmaceutical company to apply its NetraAI platform to a Phase 3 clinical trial for a novel psychiatric medicine.
• The agreement involves deploying proprietary AI methodology to analyze multidimensional clinical data, aiming to identify explainable subpopulations related to treatment response, placebo response, and adverse events.
• This engagement highlights the company's continued industry penetration and expansion of its AI-driven project portfolio in neuroscience, oncology, and complex pain.

Key Details

• Contract Counterparty: A leading global biopharmaceutical company (specific name not disclosed).
• Project Scope: Application of NetraAI to a Phase 3 clinical trial of a novel psychiatric medicine.
• Technology Deployment: Netramark will use its proprietary AI methodology to analyze multidimensional clinical data.
• Key Objectives:
  • Identify explainable subpopulations associated with treatment response.
  • Identify explainable subpopulations associated with placebo response.
  • Identify explainable subpopulations associated with adverse events.
• Strategic Outcome: Insights generated will support future strategic regulatory and market access activities.
• Portfolio Expansion: The engagement extends Netramark's portfolio of AI-driven projects in neuroscience, oncology, and complex pain.
• Technical Approach: NetraAI leverages a dynamical systems framework to overcome traditional machine learning limitations, specifically designed to work effectively with small, complex clinical data sets.
• Value Proposition: The system aims to discover high-effect-size patient subpopulations and translate them into clinically meaningful enrichment criteria understandable by investigators, regulators, and clinicians.

Notable Quotes

• "This project reflects the growing recognition among biopharmaceutical companies that Netramark's explainable AI can improve the chance of trial success," said George Achilleos, chief executive officer of Netramark.
• "NetraAI aims to provide clear, scientifically and clinically interpretable outputs that sponsors can act on -- helping them to understand precisely who benefits most, why and how to design their next pivotal studies with greater confidence."